Keywords: China, Pharmaceutical market forecasts, Pricing, Essential drug list

China’s sheer size an attraction for pharma industry, but there are also problems

Article | 8 February 2010

China has maintained its fourth place in the Pharmaceutical Business Environment Ratings matrix for the 15 key markets in the Asia Pacific region from Business Monitor International. Globally, the country is placed 18th out of the 71 nations surveyed worldwide, indicating its vast potential.

Key attractions are its sheer size and the improvement of its economic and health care systems, although it is let down by, among other factors, rampant pharmaceutical piracy, substandard quality, bureaucracy and a poor legal framework. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in